PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Ultrashort DAPT Cuts Bleeding in ACS Without Raising Overall Ischemia

★ Editor's Pickdual antiplatelet therapyDAPTticagrelorprasugrelclopidogrelaspirinP2Y12 inhibitoracute coronary syndromeSTEMINSTE-ACSpercutaneous coronary interventionstent thrombosismajor bleedingmeta-analysisEast Asian paradoxsecondary prevention Cardiology

Background Information

Ultrashort DAPT reduces bleeding without raising overall ischemic events in PCI-treated ACS patients.

Balancing efficacy and bleeding risk in dual antiplatelet therapy (DAPT) is crucial for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Ultrashort DAPT reduced major bleeding (HR: 0.47) without increasing major adverse cardiac and cerebrovascular events (MACCE) risk overall, but MACCE risk increased in STEMI cases. The study supports using ultrashort DAPT followed by monotherapy in ACS patients post-PCI for reduced bleeding, with careful consideration for STEMI and ethnicity impacts. Ultrashort DAPT may benefit ACS patients needing PCI by lowering bleeding risk without overall MACCE increase.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Hendrianus H, Gorog DA, Tantry US, Navarese EP, Lee SY, Cho JH, Jo J, Bae J, Ha SY, Honda S, Yasuda S, Widyantoro B, Soerianata S, Gurbel PA, Kim SW, Jeong YH

Citation: Hendrianus H, Gorog DA, Tantry US, et al. Ultrashort vs Standard-Duration Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing PCI: A Meta-Analysis. JACC. Cardiovascular interventions. 2026;19(17):2311-2329. doi:10.1016/j.jcin.2026.07.012

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.